Literature DB >> 3058212

Effects of chronic glucagon administration on cholesterol and bile acid metabolism.

C Guettet1, D Mathe, M Riottot, C Lutton.   

Abstract

Male adult Wistar rats received daily, at 9 a.m. and 5 p.m., 10 micrograms of Zn-protamine glucagon for 21 days by subcutaneous injections. The blood glucose level was not significantly modified. Cholesterol and triacylglycerol levels were decreased by 40 and 70% in plasma but not in the liver. The rates of cholesterol turnover processes were determined in vivo with an isotope balance method. Internal secretion of cholesterol (13.8 +/- 0.5 mg/day per rat in control rats and 22.4 +/- 0.9 mg/day per rat in glucagon-treated rats) and cholesterol transformation into bile acids were strikingly increased by chronic administration of glucagon. Biliary secretion rates of bile acids measured by a wash-out method were increased by 139%, while the intestinal bile acid pool was not changed. The enterohepatic cycle number was increased from five per day in control rats to nine per day in glucagon-treated rats. An increased turnover rate of the exchangeable cholesterol would explain the hypocholesterolemic effect of glucagon.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3058212     DOI: 10.1016/0005-2760(88)90283-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  The glucagon receptor is required for the adaptive metabolic response to fasting.

Authors:  Christine Longuet; Elaine M Sinclair; Adriano Maida; Laurie L Baggio; Marlena Maziarz; Maureen J Charron; Daniel J Drucker
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

2.  Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1.

Authors:  Toshiyuki Nakamura; Norihito Shibata; Takako Nishimoto-Shibata; Dongdong Feng; Mamoru Ikemoto; Kiyoto Motojima; Naoyuki Iso-O; Kazuhisa Tsukamoto; Masafumi Tsujimoto; Hiroyuki Arai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-08       Impact factor: 11.205

3.  Biliary response to glucagon in humans.

Authors:  G D Branum; B A Bowers; C R Watters; J Haebig; G Cucchiaro; M Farouk; W C Meyers
Journal:  Ann Surg       Date:  1991-04       Impact factor: 12.969

Review 4.  The metabolic actions of glucagon revisited.

Authors:  Kirk M Habegger; Kristy M Heppner; Nori Geary; Timothy J Bartness; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

5.  Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats.

Authors:  C Guettet; N Rostaqui; D Mathé; B Lecuyer; N Navarro; B Jacotot
Journal:  Lipids       Date:  1991-06       Impact factor: 1.880

6.  Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice.

Authors:  Xiao C Li; Tang-Dong Liao; Jia L Zhuo
Journal:  Clin Sci (Lond)       Date:  2008-05       Impact factor: 6.124

Review 7.  Elusive liver factor that causes pancreatic α cell hyperplasia: A review of literature.

Authors:  Run Yu; Yun Zheng; Matthew B Lucas; Yun-Guang Tong
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

8.  Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans.

Authors:  Changting Xiao; Mirjana Pavlic; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

9.  Glucagon Receptor Signaling and Lipid Metabolism.

Authors:  Katrine D Galsgaard; Jens Pedersen; Filip K Knop; Jens J Holst; Nicolai J Wewer Albrechtsen
Journal:  Front Physiol       Date:  2019-04-24       Impact factor: 4.566

10.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.